Korro Bio (KRRO) Expected to Announce Earnings on Wednesday

Korro Bio (NASDAQ:KRRO) will likely be posting its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Korro Bio to post earnings of ($1.7267) per share and revenue of $0.7610 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Korro Bio (NASDAQ:KRRO) last released its earnings results on Thursday, March 12th. The company reported ($5.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.93) by ($3.39). The company had revenue of $1.29 million for the quarter, compared to analyst estimates of $0.43 million. Korro Bio had a negative return on equity of 115.95% and a negative net margin of 1,834.48%. On average, analysts expect Korro Bio to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Korro Bio Price Performance

KRRO stock opened at $13.57 on Monday. The company has a market cap of $195.68 million, a PE ratio of -1.09 and a beta of 3.07. The business has a 50-day simple moving average of $12.33 and a 200 day simple moving average of $14.44. Korro Bio has a 52 week low of $5.20 and a 52 week high of $55.89.

Insider Transactions at Korro Bio

In other Korro Bio news, major shareholder Paul Edward Walker bought 207,100 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The shares were acquired at an average cost of $11.11 per share, for a total transaction of $2,300,881.00. Following the transaction, the insider directly owned 1,297,893 shares in the company, valued at approximately $14,419,591.23. This represents a 18.99% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Anthony A. Jr. Florence purchased 207,100 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average price of $11.11 per share, for a total transaction of $2,300,881.00. Following the acquisition, the insider owned 1,297,893 shares of the company’s stock, valued at $14,419,591.23. This trade represents a 18.99% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders purchased 1,657,320 shares of company stock valued at $18,412,560. 4.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Korro Bio

Hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. bought a new position in shares of Korro Bio in the 3rd quarter worth about $39,000. Algert Global LLC bought a new stake in shares of Korro Bio during the 3rd quarter valued at about $340,000. Wells Fargo & Company MN grew its stake in Korro Bio by 45.5% during the fourth quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock worth $60,000 after purchasing an additional 2,352 shares during the period. Alliancebernstein L.P. bought a new stake in Korro Bio in the third quarter worth approximately $369,000. Finally, Blair William & Co. IL bought a new stake in Korro Bio in the third quarter worth approximately $467,000. Institutional investors own 13.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on KRRO. Raymond James Financial raised shares of Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 price target for the company in a report on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Korro Bio in a research report on Wednesday, April 8th. Cantor Fitzgerald upped their target price on Korro Bio from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Friday, March 13th. William Blair raised Korro Bio from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th. Finally, Clear Str upgraded Korro Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Korro Bio has an average rating of “Moderate Buy” and a consensus target price of $37.29.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.